GCK抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P10908(GCK Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P10908(GCK Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

Glucokinase (GCK), a key enzyme in glucose metabolism, serves as a glucose sensor in pancreatic β-cells and hepatocytes, regulating insulin secretion and hepatic glucose uptake. GCK antibodies are immunological tools developed to detect and study this enzyme's expression, localization, and function in metabolic research. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate GCK-related pathologies, particularly diabetes mellitus.

Mutations in the GCK gene are linked to maturity-onset diabetes of the young type 2 (MODY2), characterized by mild fasting hyperglycemia. GCK antibodies help identify protein expression changes in such genetic disorders, aiding in mechanistic studies of glucose homeostasis. Additionally, autoantibodies against GCK have been explored in type 1 diabetes research, though their pathogenic role remains less defined compared to classic autoantigens like GAD65.

The development of high-specificity GCK antibodies has advanced understanding of tissue-specific GCK regulation and its interaction with glucokinase regulatory protein (GKRP) in the liver. Such tools are critical for dissecting molecular pathways in diabetes and evaluating therapeutic agents targeting GCK activation or inhibition. Commercial GCK antibodies are typically validated across human, rodent, and other model organisms, reflecting GCK's evolutionary conservation. Limitations include cross-reactivity risks with other hexokinases, underscoring the need for rigorous validation in experimental systems.